Ladasten

Ladasten (bromantane analog; N-(2-adamantyl)-N-(4-bromophenyl)amine derivative; INN bromantane in some sources but distinguished by the longer-acting Russian preparation; CAS for bromantane parent 40165-90-2) is an adamantane-class atypical psychostimulant and actoprotectant developed at the Russian Academy of Sciences and registered by the Russian Ministry of Health in the early 2000s for the treatment of asthenia and idiopathic chronic fatigue. Ladasten is closely related to bromantane and shares the dual immunomodulatory and dopaminergic profile of that parent compound, but Russian-language pharmacology reports describe a longer plasma half-life and a more pronounced antiasthenic effect at lower mass doses (50 to 100 mg daily versus 100 to 200 mg for bromantane). Mechanism is multifactorial and incompletely characterized in Western pharmacology: principal effects include induction of tyrosine hydroxylase and aromatic L-amino acid decarboxylase transcripts in mesolimbic dopaminergic neurons (driving sustained dopamine biosynthesis rather than release-mediated stimulation), modulation of GABA-A and serotonergic tone, and immunorestorative activity in stress models. The behavioral signature is anxiolysis without sedation combined with restoration of physical and cognitive performance under fatigue conditions, distinguishing the compound from classical psychostimulants and from benzodiazepine anxiolytics. Western clinical trial data are absent. Published Russian Phase 3 data describe efficacy in neurasthenia and post-infectious asthenia at 50 to 100 mg per day for 28 days. The compound is not approved by FDA, EMA, or any regulatory authority outside the Russian Federation and Eastern European member states; the published evidence base is dominated by a single research-clinical group, which is the principal limitation. Adverse event profile is benign at registered doses, with mild gastrointestinal upset and transient activation reported.